(19)
(11)EP 2 981 274 B1

(12)EUROPEAN PATENT SPECIFICATION

(45)Mention of the grant of the patent:
06.05.2020 Bulletin 2020/19

(21)Application number: 14779522.3

(22)Date of filing:  03.04.2014
(51)International Patent Classification (IPC): 
C12N 1/20(2006.01)
A61P 19/10(2006.01)
C12R 1/225(2006.01)
A61K 35/747(2015.01)
A23L 33/135(2016.01)
C12R 1/25(2006.01)
(86)International application number:
PCT/SE2014/050399
(87)International publication number:
WO 2014/163568 (09.10.2014 Gazette  2014/41)

(54)

PROBIOTIC STRAINS FOR USE IN TREATMENT OR PREVENTION OF OSTEOPOROSIS

PROBIOTISCHE STÄMME ZUR VERWENDUNG BEI DER BEHANDLUNG ODER PRÄVENTION VON OSTEOPOROSE

SOUCHES PROBIOTIQUES DESTINÉES AU TRAITEMENT OU À LA PRÉVENTION DE L'OSTÉOPOROSE


(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30)Priority: 03.04.2013 SE 1350414
20.12.2013 SE 1351571

(43)Date of publication of application:
10.02.2016 Bulletin 2016/06

(73)Proprietor: Probi AB
223 70 Lund (SE)

(72)Inventors:
  • BERGGREN, Anna
    S-247 47 Flyinge (SE)
  • LARSSON, Niklas
    S-226 49 Lund (SE)
  • ÖNNING, Gunilla
    S-243 30 Höör (SE)
  • LAZOU AHRÉN, Irini
    S-226 53 Lund (SE)
  • SJÖGREN, Klara
    S-439 55 Åsa (SE)
  • OHLSSON, Claes
    S-421 67 Västra Frölunda (SE)

(74)Representative: Potter Clarkson 
The Belgrave Centre Talbot Street
Nottingham NG1 5GG
Nottingham NG1 5GG (GB)


(56)References cited: : 
WO-A1-99/02170
WO-A1-2007/040444
JP-A- 2009 114 111
KR-A- 20130 002 543
WO-A1-2007/004966
WO-A2-01/15715
JP-A- 2009 114 112
  
  • SJOGREN KLARA ET AL: "Probiotics Protect Mice from Ovariectomy Induced Bone-Loss", JOURNAL OF BONE AND MINERAL RESEARCH, vol. 28, no. Suppl. 1, February 2013 (2013-02), page MO0419, XP008181376, & ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-BONE-AND-MINERAL-RESE ARCH; BALTIMORE, MD, USA; OCTOBER 04 -07, 2013 ISSN: 0884-0431
  • CHIANG SHEN-SHIH ET AL: "Effect of bioactive compounds in lactobacilli-fermented soy skim milk on femoral bone microstructure of aging mice", JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, vol. 92, no. 2, January 2012 (2012-01), pages 328-335, XP002761259, ISSN: 0022-5142
  • OHLSSON CLAES ET AL: "Probiotics Protect Mice from Ovariectomy-Induced Cortical Bone Loss", PLOS ONE, vol. 9, no. 3, March 2014 (2014-03), XP002761260, ISSN: 1932-6203
  • RAYES N. ET AL.: 'Prebiotics, probiotics, synbiotics in surgery - are they only trendy, truly effective or even dangerous?' LANGENBECK'S ARCHIVES OF SURGERY vol. 394, no. 3, 2009, pages 547 - 555, XP019715283
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).


Description

Technical field of the invention



[0001] The present invention relates to the probiotic strain Lactobacillus paracasei 8700:2, DSM 13434, or the probiotic strain Lactobacillus paracasei 8700:2, DSM 13434, in combination with at least one probiotic strain of Lactobacillus plantarum, for use in increasing the absorption of Ca2+ ions in the treatment or prevention of osteoporosis, and/or in increasing the absorption of Ca2+ ions in the treatment or prevention of bone loss, in a mammal, preferably in a human.

Background Art



[0002] Osteoporosis is a disease in which bones become fragile and more likely to fracture. Usually the bone loses density, which measures the amount of calcium and minerals in the bone. Osteoporosis is the most common type of bone disease. About half of all women over the age of 50 will have a fracture of the hip, wrist, or vertebra (bone of the spine) during their lifetime. Bone is living tissue. Existing bone is constantly being replaced by new bone. Osteoporosis occurs when the body fails to form enough new bone, when too much existing bone is reabsorbed by the body, or both. Calcium is one of the important minerals needed for bones to form. If you do not get enough calcium and vitamin D, or your body does not absorb enough calcium from your diet, your bones may become brittle and more likely to fracture. A drop in estrogen in women at the time of menopause and a drop in testosterone in men is a leading cause of bone loss.

[0003] Fractures caused by osteoporosis constitute a major health concern and result in a huge economic burden on health care systems. The lifetime risk of any osteoporotic fracture is high in the western world (around 50% for women and 20% for men) and fractures are associated with significant mortality and morbidity. Cortical bone constitutes approximately 80% of the bone in the body and several studies have shown that cortical bone is the major determinant of bone strength and thereby fracture susceptibility. Bone loss after the age of 65 is mainly due to loss in cortical bone and not trabecular bone (Lancet, 2010, May 15; 375(9727): 1729-36).

[0004] The skeleton is remodeled by bone forming osteoblasts (OBs) and bone resorbing osteoclasts (OCLs). Macrophage colony stimulating factor (M-CSF) increases proliferation and survival of OCLs precursor cells as well as up-regulates expression of receptor activator of nuclear factor-κB (RANK) in OCL. This allows RANK ligand (RANKL) to bind and start the signalling cascade that leads to OCL formation. The effect of RANKL can be inhibited by Osteoprotegerin (OPG), which is a decoy receptor for RANKL.

[0005] The association between inflammation and bone loss is well established and in auto-immune diseases osteoclastic bone resorption is driven by inflammatory cytokines produced by activated T-cells. In addition, several studies demonstrate that low-grade systemic inflammation, indicated by moderately elevated serum levels of high sensitivity C-reactive protein (hsCRP), associate with low BMD, elevated bone resorption and increased fracture risk. The estrogen deficiency that occurs after menopause results in increased formation and prolonged survival of osteoclasts. This is suggested to be due to a number of factors including loss of the immunosuppressive effects of estrogen, resulting in increased production of cytokines promoting osteoclastogenesis, and direct effects of estrogen on OCLs. In line with these data, blockade of the inflammatory cytokines TNFα and IL-1 leads to a decrease in bone resorption markers in early postmenopausal women.

[0006] In recent years, the importance of the gut microbiota (GM) for both health and disease has been intensively studied. The GM consists of trillions of bacteria which collectively contain 150-fold more genes than our human genome. It is acquired at birth and, although a distinct entity, it has clearly coevolved with the human genome and can be considered a multicellular organ that communicates with and affects its host in numerous ways. The composition of the GM is modulated by a number of environmental factors such as diet and antibiotic treatments. Molecules produced by the gut bacteria can be both beneficial and harmful and are known to affect endocrine cells in the gut, the enteric nervous system, gut permeability and the immune system. Perturbed microbial composition has been postulated to be involved in a range of inflammatory conditions, within and outside the gut including Crohn's disease, ulcerative colitis, rheumatoid arthritis, multiple sclerosis, diabetes, food allergies, eczema and asthma as well as obesity and the metabolic syndrome.

[0007] Probiotic bacteria are defined as live microorganisms which when administered in adequate amounts confer a health benefit on the host and are believed to alter the composition of the gut microbiota. The suggested underlying mechanisms are manifold including increased solubility and absorption of minerals, enhanced barrier function and modulation of the immune system.

[0008] In Gilman et al, The effect of Probiotic Bacteria on Transepithelial Calcium Transport and Calcium uptake in Human Intestinal-like Caco-2 cells, Curr. Issues Intestinal Microbial. 7: 1-6, a strain of Lactobacillus salivarius (UCC 118) and a strain of Bifidobacterium infantis (UCC 35624) was tested on calcium uptake and transepithelial calcium transport in human intestinal-like Caco-2 cells in culture. Said strains had no effect on transepithelial calcium transport in fully differentiated 16-d old Caco-2 cells. Calcium uptake into the Caco-2 cell monolayers after 24 h was significantly higher in the cells exposed to Lactobacillus salivarius.

[0009] WO99/02170 describes the use of lactobacilli in the preparation of non-fermented enteral compositions for facilitating or increasing the absorption of minerals from the diet such as calcium, zinc, iron and magnesium. The experiments performed therein, in supporting said claimed absorption, are an in vitro model of calcium transportation using Caco-2 intestinal lines (a carcinogenic cell line).

[0010] KR101279852 (KR 2013-0002543) discloses compositions for prevention or treatment of osteoporosis containing calcium and magnesium in addition to specific lactic acid bacterial strains such as Streptococcus thermophilus with deposition number KCTC11870BP, Lactobacillus rhamnosus with deposition number KCTC 11868BP, and Lactobacillus paracasei with deposition number KCTC11866BP.

[0011] Chiang et al (Effect of bioactive compounds in lactobacilli-fermented soy skim milk on femoral bone microstructure of aging mice, J Sci Food Agric, 2012, 92:328-335) discloses soy skim milk fermented by Lactobacillus paracasei subsp. paracasei NTU 101 and L. plantarum NTU 102, for use in attenuating aging-induced bone loss in BALB/c mice and in possibly lowering the risk of osteopenia or osteoporosis in aging.

[0012] JP 2009-114112 discloses an anti-osteoporosis agent comprising Lactobacillus paracasei KW3110 strain.

[0013] There is still a need within the art to find effective preventive and therapeutic methods against osteoporosis in humans.

Summary of the invention



[0014] The present invention is defined by the accompanying claims. The present invention relates in one aspect to the probiotic strain Lactobacillus paracasei 8700:2, DSM 13434, or the probiotic strain Lactobacillus paracasei 8700:2, DSM 13434, in combination with at least one probiotic strain of Lactobacillus plantarum, for use in increasing the absorption of Ca2+ ions in the treatment or prevention of osteoporosis, and/or in increasing the absorption of Ca2+ ions in the treatment or prevention of bone loss, in a mammal, preferably in a human.

Brief description of the figures



[0015] 

Fig. 1 discloses Ca2+ transport tested with the different bacterial strains as disclosed in experiments 1 and 2.

Fig. 2 discloses the remaining intracellular Ca2+ in the cells after 2 h as described in experiments 1 and 2.

Fig. 3 discloses the experiment design and body weight of experiment 3. Outline of experiment design (A). Eight-week-old mice were treated with either vehicle (veh), a single Lactobacillus (L) strain (L. para) or a mixture of three strains (L. mix) during 6 weeks, starting two weeks before ovx or sham surgery. The L. strains were given in the drinking water at a concentration of 109 colony-forming units (cfu)/ml while control mice received tap water with vehicle. Mice were 14-week-old at the end of the study, when tissues were collected for later analysis. Ovx resulted in an expected increased body weight compared to sham mice that was not different after probiotic treatment (B). Results are given as mean±SEM (n=9-10), ** p≤ 0.01. Student's t test ovx vs. sham.

Fig. 4 discloses that probiotics protect mice from ovx induced cortical bone-loss. Eight-week-old mice were treated with either vehicle (veh), a single Lactobacillus (L) strain (L. para) or a mixture of three strains (L. mix) during 6 weeks, starting two weeks before ovx or sham surgery to study the preventive effect of probiotic treatment on ovx induced bone-loss. At the end of the experiment, dissected femurs were analysed with high-resolution µCT and peripheral quantitative computed tomography (pQCT). Representative µCT images of one cortical section from the veh and L. mix treated sham and ovx groups (A). Cortical bone mineral content (BMC) (B) and cortical area (C) were measured by pQCT in the mid-diaphyseal region of femur. Values are given as mean±SEM, (n=9-10). ** p≤0.01, * p≤0.05. Student's t test ovx vs. sham. # p≤0.05, ANOVA followed by Dunnett's post hoc test within the groups, ovx L. Para and L. mix vs. ovx veh.

Fig. 5 discloses that probiotics reduces expression of inflammatory cytokines and the RANKL/OPG ratio in cortical bone. QRT-PCR analysis of the expression of genes known to promote bone resorption; (A) Tumor Necrosis Factor alpha (TNFα), (B) Interleukin-1β (IL-1β), (C) Interleukin-6 (IL-6), (D) Ratio of Receptor activator of nuclear factor kappa-B ligand (RANKL) and Osteoprotegerin (OPG), and individual graphs for (E) OPG, (F) RANKL and genes known to promote bone formation; (G) Osterix, (H) Collagen, type I, αl (Col1α1) and (I) osteocalcin in cortical bone from 14-week-old ovariectomized (ovx) mice treated with either vehicle (veh) or a mixture of three probiotic Lactobacillus strains (L. mix) during 6 weeks, starting two weeks before ovx or sham surgery to study the preventive effect of probiotic treatment on ovx-induced bone-loss. Values are given as mean±SEM, n=9-10. *P≤0.05 versus veh treatment, Student's t-test.

Fig. 6 discloses that the fractional excretion of Ca was increased by ovx in the veh treated but not in the L. para or the L. mix treated mice. Ca and creatinine were measured in serum and urine from 14-week-old mice that had been treated with vehicle (veh), a single Lactobacillus (L) strain (L. para) or a mixture of three strains (L. mix) during 6 weeks, starting two weeks before ovx or sham surgery. Urinary fractional Ca excretion was calculated with the formula FECa = (urine Ca x serum creatinine)/(serum Ca x urine creatinine). Values are given as mean±SEM, n=5-10 in each group. * p≤0.05. Student's t test ovx vs. sham. # p≤0.05, ANOVA followed by Dunnett's post hoc test within the groups, ovx L. Para and L. mix vs. ovx veh.


Description of the invention



[0016] The present invention relates, in an embodiment, to the probiotic strain Lactobacillus paracasei 8700:2, DSM 13434, or the probiotic strain Lactobacillus paracasei 8700:2, DSM 13434, in combination with at least one probiotic strain of Lactobacillus plantarum, for use in increasing the absorption of Ca2+ ions in the treatment or prevention of osteoporosis, and/or in increasing the absorption of Ca2+ ions in the treatment or prevention of bone loss, in a mammal, preferably in a human.

[0017] The present disclosure also relates to at least one probiotic strain for use in the treatment or prevention of osteoporosis by preventing cortical bone loss, by preventing bone mineral content loss, and by preventing bone-resorption.

[0018] Cortical bone constitutes approximately 80% of the bone in the body and several studies have shown that cortical bone is the major determinant of bone strength and thereby fracture susceptibility. It has been shown in the experiments herein that a probiotic strain of the species Lactobacillus paracasei either alone or in combination with strains of the species Lactobacillus plantarum prevents cortical bone loss. It is also indicated in the experiments herein that probiotic treatment alters the immune status in bone resulting in attenuated bone resorption. In addition, it is also shown in the experiments herein that bone mineral content was not reduced in the probiotic group compared to vehicle group (Figure 4a-c). Bone mineral content in cortical bone was higher in both probiotic groups compared to vehicle group (p<0.05, Figure 4b).

[0019] The present disclosure also relates to the probiotic strain Lactobacillus paracasei 8700:2, DSM 13434, or the probiotic strain Lactobacillus paracasei 8700:2, DSM 13434, in combination with at least one probiotic strain of Lactobacillus plantarum, for use in the treatment or prevention of osteoporosis, for preventing bone mineral content loss, for preventing bone-loss in a mammal, preferably in a human.

[0020] The present disclosure also relates to the probiotic strain Lactobacillus paracasei 8700:2, DSM 13434, or the probiotic strain Lactobacillus paracasei 8700:2, DSM 13434, in combination with at least one probiotic strain chosen from Lactobacillus plantarum, for use in preventing bone mineral content loss, for preventing bone-loss in a mammal, preferably in a human.

[0021] In an embodiment of the invention at least two or more Lactobacillus plantarum strains are used together in a combination with the probiotic strain Lactobacillus paracasei 8700:2, DSM 13434. Also disclosed is at least two or more, for example three or more, Lactobacillus paracasei strains used together in a combination with at least one Lactobacillus plantarum strain.

[0022] In an embodiment of the invention the probiotic strain is viable, inactivated or dead. In an embodiment of the invention said strains are present in a composition comprising additionally at least one carrier. The carrier could be any carrier conventionally used in for instance a dietary supplement. The carrier may be any cereal based carrier such as an oatmeal carrier or barley carrier that can be used in a functional food or any other kind of food. The carrier may be water or any other aqueous solvent in which the probiotic strain is mixed before intake.

[0023] The composition may be supplemented with additional Ca2+ in the form of for instance a salt, e.g. calcium carbonate, calcium chloride, calcium salts of citric acid, calcium gluconate, calcium glycerophosphate, calcium lactate, calcium oxide, calcium sulphate. The recommended daily intake (RDI) of Ca2+ is 800 mg. The amount of Ca2+ in the composition may be in the range of 10-40% of the RDI, preferably in the range of 15-30% of the RDI. Thus, the amount of Ca2+ e.g. in the form of a salt in the composition may be in the range 80 - 320 mg, preferably 120 - 240 mg. The amount of Ca2+ added to the composition could be adjusted to any amount within the above range so that the composition is still stable and provides its beneficial effects.

[0024] The composition may be a dry, non-fermented composition or a fermented composition. In the case of a dry, non-fermented composition, the fermentation takes place after intake of the composition by an individual, i.e. in the gastrointestinal tract. In addition, the strains may be present in the composition as freeze-dried strains.

[0025] The probiotic strain of Lactobacillus paracasei may be chosen from Lactobacillus paracasei 8700:2, DSM 13434. Also disclosed is the probiotic strain Lactobacillus paracasei 02:A, DSM 13432. The probiotic strain of Lactobacillus plantarum may be chosen from Lactobacillus plantarum 299, DSM 6595, Lactobacillus plantarum 299v, DSM 9843, Lactobacillus plantarum HEAL 9, DSM 15312, Lactobacillus plantarum HEAL 19, DSM 15313, and Lactobacillus plantarum HEAL 99, DSM 15316.

[0026] Lactobacillus paracasei 8700:2, DSM 13434, and Lactobacillus paracasei 02:A, DSM 13432, were both deposited on 10 April 2000 at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH.

[0027] Lactobacillus plantarum HEAL 9, DSM 15312, Lactobacillus plantarum HEAL 19, DSM 15313, and Lactobacillus plantarum HEAL 99, DSM 15316, were deposited at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH on 28 November 2002.

[0028] Lactobacillus plantarum 299v, DSM 9843, was deposited on 21 March 1995 and Lactobacillus plantarum 299, DSM 6595, was deposited on 5 July 1991 at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH.

[0029] In an embodiment of the invention, the composition including the probiotic strain(s) may be chosen from the group consisting of a food product, a dietary supplement, a medical food, a functional food and a nutritional product.

[0030] In the case where said composition is a food product, it may be chosen from the group comprising beverages, yoghurts, juices, ice creams, breads, biscuits, cereals, health bars, and spreads.

[0031] When any of the above mentioned strains are used in a composition such as a dietary supplement the carrier(s) to be added are known to a skilled person. Any other ingredients that are normally used in dietary supplements are known to a skilled person and may also be added conventionally together with the strains.

[0032] In an embodiment of the invention, the above mentioned probiotic strain(s) are present in a composition in an amount from about 1x106 to about 1x1014 CFU, preferably 1x108 to 1x1012, and more preferably 1x109 to 1x1011. The strains may also be used alone in the above amount in water or any other aqueous vehicle in which the strains are added or mixed before intake.

[0033] The invention is suitable to be used by mammals, preferably any humans, such as elderly people, postmenopausal women and premenopausal women, in which bone loss, bone mineral content loss and increased bone-loss or bone resorption are or may become a problem.

[0034] Healthy people may naturally also benefit from the invention in order to stay healthy and prevent getting sick by osteoporosis.

Experimental


Experiment 1


Materials and methods


"Transport Solutions"; total volume 6 ml



[0035] The transport Solutions contained Hank's Balanced Salt solution (HBSS) with Ca and Mg, Hepes (2%), Glutamine (4 mM), D-Glc (3, 5 g/l) and CaCl2• 2 H2O (1.47 g/l). Analysis of the solution gave a [Ca2+] on10,65 mM.

"Basal solution"



[0036] Similar to the transport solution, but without the addition of external calcium. Analysis of this solution gave a [Ca2+] 1,22 mM.

Experiment 1 :



[0037] 
  1. 1. Control of the transport solution only
  2. 2. Lyophilised Lactobacillus plantarum 299 v. 0,788 mg corresponding to 4,02 x 108 bacteria/6 ml in transport solution
  3. 3. Lactobacillus plantarum 299v. 4.02 x 108 bacteria/6 ml in transport solution
  4. 4. Lactobacillus plantarum 299. 4.95 x 108 bacteria/6 ml in transport solution
  5. 5. Lactobacillus plantarum HEAL 19, 4.95 x 108 bacteria/6 ml in transport solution
  6. 6. AMJ 1277. 4.95 x 108 bacteria/6 ml in transport solution. AMJ 1277 is a mutated form of Lactobacillus plantarum 299v.

Experiment 2:



[0038] 
  1. 1. CNCM I-2332, Lactobacillus acidophilus (La10); + 4.95 x 108 bacteria/6 ml in transport solution
  2. 2. Lactobacillus plantarum 299 v. 4,02 x 108 bacteria/6 ml in transport solution
  3. 3. Control - transport solution only


[0039] All strains except strain La10 were cultured aerobically in 30 ml of MRS. (30 ° C, 210 rpm). La10 was cultured in 37 ° C and covered with sterile filtrated nitrogen before sealing. Number of inoculated cells was 3 x 108 /flask. The bacteria were precultivated over night and were in exponential phase at inoculation. The cells were harvested at OD600=0.1-0.5 and for each strain a volume corresponding to 4,02 x 108 cells was collected. These samples were centrifuged at 5000 rpm, 3 min, the supernatant was poured and the cells resuspended in NaCl (0.9%). The cells were centrifuged again and the supernatant was decanted. The now washed pellet was then suspended in the transport solution.

[0040] Caco-2 cells were washed with PBS (2 times) before the test. 45Ca Cl2 (74kBq/ml) were added to the transport solutions. The mixture was then added, in a volume of 0.5 ml, apically to Caco-2 cells growing on inserts. Each well has then obtained 6.7 x 107 bacteria/ml. Only the basal solution (1.5 ml) containing only the endogenous [Ca2 +] in HBSS (1,22 mM) was added the basal Chamber. Suspensions and controls were allowed to function on the Caco-2 cells for 2 h. They were then aspired and the cells were washed with ice-cold washing-buffer 3 times in accordance with the method described in WO99/02170. The Caco-2 cells were thereafter lysated in 0,5 ml of NaOH (0.5 M). The solutions in the basal chambers were collected for measurement of transport with the help of scintilator (Tri-carb 2800TR, Perkin Elmer). The lysates were analyzed for 45Ca, but also for protein content. All measured values for Ca2+ transport/uptake were normalized against the protein content in the respective cells. All wells were checked before and after incubation with the test solutions regarding transepithelial resistance (TEER). No differences in TEER, before and after the trials, could be seen. TEER is measured to ensure that the epithelium is not leaking. A difference in resistance after a trial may lead to the suspicion that the intercellular bonds may have been damaged by the solutions used.

Results



[0041] To enable comparison of the results from experiments 1 and 2, transport and uptake data from the studied strains have been normalised against the control solution without bacteria. All results are therefore presented as a percentage of the control (similarly to as done in WO99/02170). It should also be noted that the experiments 1 and 2 were done on days 16 and 21 of cellular culture, respectively. In general, it is observed that the standard deviations of the obtained results are relatively large. This could be due to some form of aggregation of bacteria and Ca2+, leading to a variation in the availability of Ca2+. This is not observed for the freeze-dried bacteria where the standard deviations were relatively small compared with the remaining samples.

Transport of Ca2+



[0042] The results of experiment 1 showed a significant improvement of the Ca2+ transport when the strain AMJ1277 was present (134,7 ±18,9%, p=0,002), see fig. 1. None of the other strains (Lp299v freeze-dried and viable, Lp299, Lp HEAL 19) gave significant differences in transport of Ca2+, se table 1. In experiment 2 where La10 and Lp299v were tested no significant differences in the transport of Ca2+ were detected when comparing the samples with Lp299v vs control without bacteria (p=0,2). For La10 a slight decrease of the Ca2+ transport in the presence of the same bacteria was observed (79,5 ±19,3%) and this change was significant (p=0,049).

Uptake of Ca2+



[0043] Uptake data presented here show the amount of Ca2+ present in the cells after 2 hrs. For an estimate of the actual uptake data, the intracellular amounts of Ca2+ should be added to the amount of Ca2+ detected in the lateral compartments. The sum of these data describes the total amount of Ca2+ that has been transported through the apical membrane. The results of these experiments generally shows a reduction in intracellular [Ca2+] in the presence of bacteria, compared to the bacteria-free control solutions, see Figure 2. However, only the differences of the lyophilized and viable Lp299v, were significant (p = 0.04 and p = 0.02). Note, that the intermediate intracellular Ca2+ levels are only a few percent in comparison to the transported amount of Ca2+. Due to this, the demonstrated effect of the uptake of Ca2+ do not have the same impact as the effects on transport. This can be observed for lyophilized and viable Lp 299v, which has a higher intracellular [Ca2+] but do not demonstrate an improvement in transport.

Conclusion



[0044] In the presence of the strain AMJ1277, a mutant Lactobacillus plantarum 299v, an increased transport and even a total uptake of calcium is observed compared to both the control and the remaining strains. Thus, there is variation between the strains looked at.

Experiment 3


Ovariectomized mouse-model and probiotic treatment



[0045] Ovariectomy (ovx) results in bone loss associated with altered immune status. The purpose of this experiment was to determine if probiotic treatment protects mice from ovx induced bone loss. Mice were treated with either a single Lactobacillus (L) strain, L. paracasei DSM13434 (L. para) or a mixture of three strains, L. paracasei DSM13434, L. plantarum DSM 15312 and DSM 15313 (L. mix) given in the drinking water during 6 weeks, starting two weeks before ovx.

[0046] Six-week old C57BL/6N female mice were purchased from Charles River (Germany). The mice were housed in a standard animal facility under controlled temperature (22 °C) and photoperiod (12-h light, 12-h dark) and had free access to fresh water and soy-free food pellets R70 (Lactamin AB, Stockholm, Sweden). The ovariectomized (ovx) model for osteoporosis is included in the FDA guidelines for preclinical and clinical evaluation for agents used for the treatment of postmenopausal osteoporosis. Probiotic treatment started two weeks before ovx to study the preventive effect of probiotic treatment on ovx induced bone-loss. Mice were treated with either a single Lactobacillus (L) strain, L. paracasei DSM13434 (L. para) or a mixture of three strains, L. paracasei DSM 13434, L. plantarum DSM 15312 and DSM 15313 referred to as L. mix during 6 weeks. The probiotic strains were selected based on their anti-inflammatory properties. The L. strains were given in the drinking water at a concentration of 109 colony-forming units (cfu)/ml while control mice received tap water with vehicle. Water bottles were changed every afternoon. The survival of the L. strains in the water bottles was checked regularly and after 24 h the concentration dropped one log unit to approximately 108 cfu/ml. Each mouse drank on average 4.5 ml water/day. After two weeks of probiotic treatment, the mice were either sham-operated or ovx under inhalation anesthesia with isoflurane (Forene; Abbot Scandinavia, Solna, Sweden). Four weeks after surgery, blood was collected from the axillary vein under anesthesia with Ketalar/Domitor vet, and the mice were subsequently killed by cervical dislocation. Tissues for RNA preparation were immediately removed and snap-frozen in liquid nitrogen for later analysis. Bones were excised and fixed in 4% paraformaldehyde. All animal experiments had been approved by the local Ethical Committees for Animal Research at the University of Gothenburg.

Peripheral quantitative computed tomography (pQCT)



[0047] Computed tomographic scans were performed with the pQCT XCT RESEARCH M (version 4.5B, Norland, Fort Atkinson, WI, USA) operating at a resolution of 70µm, as. Cortical bone parameters were analyzed ex vivo in the mid-diaphyseal region of the femur.

High-resolution µCT



[0048] High-resolution µCT analyses were performed on the distal femur by using an 1172 model µCT (Bruker micro-CT, Aartselaar, Belgium). The femurs were imaged with an X-ray tube voltage of 50 kV and current of 201 µA, with a 0.5-mm aluminium filter. The scanning angular rotation was 180° and the angular increment 0.70°. The voxel size was 4.48 µm isotropically. The NRecon (version 1.6.9) was employed to perform the reconstruction following the scans. In the femur, the trabecular bone proximal to the distal growth plate was selected for analyses within a conforming volume of interest (cortical bone excluded) commencing at a distance of 538.5 µm from the growth plate, and extending a further longitudinal distance of 134.5 µm in the proximal direction. Cortical measurements were performed in the diaphyseal region of femur starting at a distance of 3.59 mm from the growth plate and extending a further longitudinal distance of 134.5 µm in the proximal direction. For BMD analysis, the equipment was calibrated with ceramic standard samples.

RNA isolation and Real Time PCR



[0049] Total RNA was prepared from cortical bone (femur with the ends removed and bone marrow flushed out with PBS before freezing) and bone marrow using TriZol Reagent (Invitrogen, Lidingö, Sweden). The RNA was reverse transcribed into cDNA using High-Capacity cDNA Reverse Transcription Kit (#4368814, Applied Biosystems, Stockholm, Sweden). RT-PCR analyses were performed using the ABI Prism 7000 Sequence Detection System (PE Applied Biosystems). We used predesigned RT-PCR assays from Applied Biosystems (Sweden) for the analysis of IL-6 (Mm00446190_m1), IL-1β (Mm00434228_m1), TNFα (Mm00443258_m1), RANKL (Mm00441908_m1), OPG (Mm00435452_m1), Runx2 (Mm00501580_m1), Col1α1 (Mm00801666_g1), osteocalcin (Mm01741771_g1) and TGFβ1 (Mm03024053_m1) mRNA levels. The mRNA abundance of each gene was calculated using the "standard curve method" (User Bulletin 2; PE Applied Biosystems) and adjusted for the expression of 18S (4308329) ribosomal RNA.

Blood Analysis



[0050] Analyses were performed according to the manufacturer's instructions for serum and urine calcium (QuantiChrom™Calcium Assay Kit (DICA-500), Bioassays systems, Hayward, CA, USA), serum and urine creatinine (Mouse Creatinine Kit, Crystal Chem, Downers Grove, IL, USA). As a marker of bone resorption, serum levels of type I collagen fragments were assessed using a RatLaps ELISA kit (Nordic Bioscience Diagnostics, Herlev, Denmark). Serum levels of osteocalcin, a marker of bone formation, were determined with a mouse osteocalcin immunoradiometric assay kit (Immutopics, San Clemente, CA).

Flow Cytometry



[0051] Bone marrow cells were harvested by flushing 5 ml PBS through the bone cavity of one femur using a syringe. After centrifugation at 515 g for 5 min, pelleted cells were resuspended in Tris-buffered 0.83% NH4Cl solution (pH 7.29) for 5 min to lyse erythrocytes and then washed in PBS. Bone marrow cells were resuspended in RPMI culture medium (PAA Laboratories, Pasching, Austria) before use. The total number of leucocytes in bone marrow was calculated using an automated cell counter (Sysmex, Hamburg, Germany). For flow cytometry analyses, cells were stained with allophycocyanin (APC)-conjugated antibodies to CD4 for detection of T helper cells (Beckton-Dickinson) and fluorescein isothiocyanate (FITC)-conjugated antibodies to CD8 cytotoxic T cells (Beckton-Dickinson) or Peridinin-chlorophyll proteins (PerCP)-conjugated antibodies to Gr-1/Ly-6G (BioLegend) to eliminate granulocytes and FITC-conjugated antibodies to CD11b for detection of OCL precursor cells (Beckton-Dickinson). The cells were then subjected to fluorescence activated cell sorter analysis (FACS) on a FACSCalibur (BD Pharmingen, Franklin Lakes, NJ USA) and analyzed using FlowJo software. Results are expressed as cell frequency (%).

Statistical analyses



[0052] All the statistical results are presented as the means±SEM. Between-group differences were calculated using unpaired t tests. Comparisons between multiple groups were calculated using a one-way analysis of variance (ANOVA) followed by Dunnett's test to correct for multiple comparisons. A two-tailed p ≤ 0.05 was considered significant.

Results - Probiotic treatment protects mice from ovx-induced cortical bone loss and increased bone resorption



[0053] To determine the preventive effect of probiotic treatment on ovx-induced bone-loss, eight-week-old mice were treated with vehicle (veh), a single Lactobacillus (L) strain (L. para) or a mixture of three strains (L. mix) during 6 weeks, starting two weeks before ovx or sham surgery (Figure 3A). Uterus weight can be used as an indicator of estrogen status and ovx resulted in an expected decrease in uterus weight that was similar for all treatments (Table 2). In addition, ovx increased body weight, fat mass and thymus weight in all treatment groups (Figure 3B, Table 2).

[0054] In the vehicle treated mice, ovx decreased the cortical bone mineral content and cortical cross sectional bone area in the mid-diaphyseal region of femur (p<0.01, Figure 4a-c). Importantly, ovx did not reduce cortical bone mineral content or cortical cross sectional bone area in the L. para or the L. mix treated mice (Figure 4a-c). Cortical bone mineral content was higher in both L. para and L. mix treated ovx mice compared to veh treated ovx mice (p<0.05, Figure 4b). To determine if the preventive effect of probiotics on cortical bone is caused by affected bone resorption, serum levels of C-terminal telopeptides (RatLaps) were analyzed. Ovx increased levels of RatLaps in veh-treated mice (+45±11%, p<0.05 over sham) but not in L. para treated (20±9 %, non-significant) or L. mix treated (23±9 %, non-significant) mice. Bone formation, as indicated by serum osteocalcin, was not significantly affected by probiotic treatment (data not shown). Trabecular bone parameters (BV/TV and trabecular BMD) in the distal metaphyseal region of femur were significantly reduced by ovx in all treatment groups (p<0.05 Table 2). These findings demonstrate that probiotic treatment protects mice from ovx-induced cortical bone loss and increased bone resorption.

Probiotics reduces expression of inflammatory cytokines and the RANKL/OPG ration in cortical bone



[0055] To investigate the mechanism for the effect of probiotic treatment on ovx-induced cortical bone loss, we measured bone related mRNA transcripts in cortical bone (Figure 5). The mRNA levels of TNFα, an inflammatory cytokine produced by myeloid cells that promotes osteoclastogenesis, and IL-1β, a downstream regulator of the effects of TNFα on bone, were significantly decreased by probiotic treatment compared to vehicle treatment in ovx mice (TNFα -46%, p<0.05; IL-1β - 61%, p<0.05, Figure 5a and 5b). The expression of, IL-6 did not differ between treatments although there was a tendency to decreased expression in the probiotic treatment group (-20%, p=0.12, Figure 5c).

[0056] The RANKL/osteoprotegerin (OPG) ratio is a major determinant of osteoclastogeneisis and, thereby, bone resorption. Importantly, probiotic treatment decreased the RANKL/ OPG ratio (-45%, p<0.05 compared with veh, Figure 5d) and this was caused by an increased OPG expression (OPG; +28%, p<0.05 and RANKL; +1%, non-significant, Figure 5e, f). In contrast, the mRNA levels of three osteoblast-associated genes, Osterix, Col1α1 and osteocalcin, were not affected by probiotic treatment (Figure 5g-h).

Immune Status in Bone Marrow



[0057] Some of the anti-inflammatory effects exerted by probiotic bacteria are thought to be mediated via the induction of regulatory T (Treg) cells. FACS analysis of bone marrow showed that the frequency of Treg (CD4+ CD25+ Foxp3+) cells was decreased by ovx in veh treated but not in probiotic-treated mice (Table 2). Treg cells are dependent on TGFβ for their induction and maintenance and the expression of TGFβ1 was increased in bone marrow from ovx probiotic-treated compared with ovx vehicle treated mice (+77±19%, p<0.01).

[0058] It was also examined if probiotic treatment modulated the frequency of osteoclast precursor cells (preOCLs) in bone marrow. The frequency of preOCLs (CD11b+ Gr1-) in bone marrow was not affected by ovx in any of the treatment groups (Table 2).

Mineral Metabolism



[0059] The urinary fractional excretion of Calcium (FECa = (urine Ca × plasma creatinine)/(plasma Ca × urine creatinine)) was increased by ovx in veh treated mice (+86%, p<0.05, Figure 6). The ovx induced increase in FECa was completely prevented by probiotic treatment suggesting enhanced accretion of Ca (Figure 6). There was a tendency of increased serum levels of Ca after ovx in veh but not probiotic treated mice (+13%, p=0.05, Table 3). The urine Ca/creatinine ratio was not affected by ovx in any of the treatment groups (Table 3).

Table 2
 ShamOvx
 VehL. ParaL. MixVehL. ParaL. Mix
Estrogen Responsive Organ Weights      
Uterus weight (mg) 45.9±4.8 65.9±12.5 65.2±10.4 8.95±0.7** 11.0±3.2** 6.9±0.3**
Gonadal Fat (mg) 371±41 296±40 326±40 597±68* 630±28** 577±58**
Thymus weight (mg) 55.5±3.2 53.6±5.1 47.7±2.6 93.9±4.2** 90.0±5.1** 73.7±5.2**#
Trabecular Bone      
BV/TV (%) 16.2±0.7 16.8±0.8 17.4±0.8 13.2±0.7** 14.4±0.6* 13.8±0.5**
BMD (mg/cm3) 322±9 331±12 344±8 285±9* 302±7* 298±7**
Immune Cells in Bone marrow      
Treg (CD4+ Foxp3+ CD25+) (%) 0.117±0.023 0.109±0.017 0.090±0.017 0.054±0.004* 0.069±0.008 0.070±0.014
preOCLs (CD11b+ Gr1-) (%) 7.77±1.01 6.75±1.20 8.94±1.17 6.70±0.94 7.17±1.32 8.57±1.50
Table 2. Estrogen Responsive Organ Weights, Trabecular Bone and Immune Cells in Bone Marrow Eight-week-old mice. Trabecular bone parameters were analysed by high resolution µCT in the distal metaphyseal region of femur; Trabecular bone volume as a percentage of tissue volume (BV/TV); Trabecular bone mineral density (BMD). Femur bone marrow cells were stained with antibodies recognizing CD4, Foxp3, CD25, CD11b and Gr1. Values represent the percentage of Treg (CD4+ Foxp3+ CD25+) or preOCLs (CD11b+ Gr1-) in the total bone marrow population. Results are given as mean±SEM, n=6-10 in each group. ** p< 0.01, * p< 0.05, Student's t test ovx vs. sham, # p< 0.05, ANOVA-Dunnets within groups .
Table 3
 ShamOvx
 VehL. ParaL. MixVehL. ParaL. Mix
Serum Ca 9.1±0.4 9.2±0.4 8.5±0.3 10.3±0.4(*) 9.3±0.4 8.7±0.3#
 (mg/dl)            
Urine 6.7±0.7 6.3±0.4 5.4±0.6 8.5±1.3 5.9±0.5 5.6±0.7
 Ca/Creatinine            
 Ratio            
Table 3. Mineral Metabolism Calcium and creatinine were measured in serum and urine from 14-week old mice. Results are given as mean±SEM, n=5-10 in each group. ** p< 0.01, * p< 0.05, (*) p=0.05. Student's t test ovx vs. sham, # p< 0.05, ANOVA-Dunnets within groups.


[0060] In conclusion, the data of the present invention show that probiotics in the drinking water reduces ovx induced cortical bone-loss suggesting a therapeutic potential for probiotics in the treatment of postmenopausal osteoporosis. In addition, the results support a role of the gut microbiota for the regulation of bone mass.

[0061] Both the L. para and the L. mix treatment protected mice from ovx-induced cortical bone loss and increased bone resorption. Cortical bone mineral content was higher in both L. para and L. mix treated ovx mice compared to vehicle (veh) treated ovx mice. The urinary fractional excretion of calcium and the resorption marker RatLaps were increased by ovx in the veh treated but not in the L. para or the L. mix treated mice. Thus, probiotics inhibit ovx induced excretion of calcium in urine. Probiotic treatment reduced the expression of the two inflammatory cytokines, TNFα and IL-1β, and increased the expression of OPG in cortical bone of ovx mice. In addition, ovx decreased the frequency of regulatory T-cells (CD4+ CD25+ Foxp3+) in bone marrow of veh treated but not probiotic treated mice. Thus, probiotics inhibit the ovx induced decrease in frequency of regulatory T-cells in bone marrow. In addition, probiotics increased the expression of TGFb1 in bone marrow and probiotics inhibit the ovx induced increase of the resorption marker Rat Lap. In conclusion, treatment with L. para or the L. mix prevents ovx induced cortical bone loss. The findings of the invention indicate that these probiotic treatments alter the immune status in bone as demonstrated by reduced expression of inflammatory cytokines and increased expression of OPG, resulting in attenuated bone resorption in ovx mice.

Experiment 4



[0062] In this experiment it will be tested if the same probiotics as mentioned above will affect the same parameters as above (i.e. cortical bone mass, bone mineral content, bone resorption) in female mice that already have been ovariectomized and thus already have lost bone-mass. Ovariectomized female mice is a well established model of postmenopausal bone loss in women. The time line of the experiments will be as indicated below.
Ovariectomize mice => 4 weeks => Probiotic treatment for 6 weeks => End
Probiotics will be given in drinking water and will begin first after 4 weeks after ovariectomization. Dose will be 109 cfu/ml/day and ovariectomization will take place at 9-10 weeks of age. Analyses after ended experiment will be (CT) of the bone to measure the density and thickness, as well as serum analysis and bone markers.


Claims

1. Lactobacillus paracasei 8700:2, DSM 13434, for use in increasing the absorption of Ca2+ ions in the treatment or prevention of osteoporosis, and/or in increasing the absorption of Ca2+ ions in the treatment or prevention of bone loss, in a mammal.
 
2. Lactobacillus paracasei 8700:2, DSM 13434, for use according to claim 1, in combination with at least one probiotic strain of Lactobacillus plantarum.
 
3. Lactobacillus paracasei 8700:2, DSM 13434, for use according to claim 2, wherein said at least one probiotic strain of Lactobacillus plantarum is chosen from Lactobacillus plantarum 299, DSM 6595, Lactobacillus plantarum 299v, DSM 9843, Lactobacillus plantarum HEAL 9, DSM 15312, Lactobacillus plantarum HEAL 19, DSM 15313, and Lactobacillus plantarum HEAL 99, DSM 15316.
 
4. Lactobacillus paracasei 8700:2, DSM 13434, for use according to claim 1, in combination with Lactobacillus plantarum HEAL 9, DSM 15312, and Lactobacillus plantarum HEAL 19, DSM 15313.
 
5. Lactobacillus paracasei 8700:2, DSM 13434, for use according to any one of claims 1-4, wherein the mammal is a human.
 
6. A composition comprising Lactobacillus paracasei 8700:2, DSM 13434, according to any one of claims 1-5, for use in increasing the absorption of Ca2+ ions in the treatment or prevention of osteoporosis, and/or in increasing the absorption of Ca2+ ions in the treatment or prevention of bone loss, in a mammal, wherein the composition comprises additionally at least one carrier.
 
7. A composition comprising Lactobacillus paracasei 8700:2, DSM 13434, for use according to claim 6, wherein said composition is provided in the form of a food product, a dietary supplement, a medical food, a functional food or a nutritional product.
 
8. Lactobacillus paracasei 8700:2, DSM 13434, for use according to any one of claims 1-5, or a composition comprising Lactobacillus paracasei 8700:2, DSM 13434, for use according to claim 6 or 7, wherein the Lactobacilli are present in an amount from about 1x106 to about 1x1014 CFU.
 
9. Lactobacillus paracasei 8700:2, DSM 13434, for use according to claim 8 or a composition comprising Lactobacillus paracasei 8700:2, DSM 13434, for use according to claim 8, wherein the Lactobacilli are present in an amount from about 1x108 to about 1x1012 CFU.
 
10. Lactobacillus paracasei 8700:2, DSM 13434, for use according to claim 9 or a composition comprising Lactobacillus paracasei 8700:2, DSM 13434, for use according to claim 9, wherein the Lactobacilli are present in an amount from about 1x109 to about 1x1011 CFU.
 
11. Lactobacillus paracasei 8700:2, DSM 13434, for use according to any one of claims 1-5 or 8-10, or a composition comprising Lactobacillus paracasei 8700:2, DSM 13434, for use according to any one of claims 6-10, wherein the osteoporosis is postmenopausal osteoporosis.
 


Ansprüche

1. Lactobacillus paracasei 8700:2, DSM 13434, zur Verwendung bei der Erhöhung der Absorption von Ca2+-Ionen bei der Behandlung oder Vorbeugung von Osteoporose und/oder bei der Erhöhung der Absorption von Ca2+-Ionen bei der Behandlung oder Vorbeugung von Knochenschwund, bei einem Säuger.
 
2. Lactobacillus paracasei 8700:2, DSM 13434, zur Verwendung nach Anspruch 1, in Kombination mit mindestens einem probiotischen Stamm von Lactobacillus plantarum.
 
3. Lactobacillus paracasei 8700:2, DSM 13434, zur Verwendung nach Anspruch 2, wobei der mindestens eine probiotische Stamm von Lactobacillus plantarum aus Lactobacillus plantarum 299, DSM 6595, Lactobacillus plantarum 299v, DSM 9843, Lactobacillus plantarum HEAL 9, DSM 15312, Lactobacillus plantarum HEAL 19, DSM 15313 und Lactobacillus plantarum HEAL 99, DSM 15316 ausgewählt ist.
 
4. Lactobacillus paracasei 8700:2, DSM 13434, zur Verwendung nach Anspruch 1, in Kombination mit Lactobacillus plantarum HEAL 9, DSM 15312 und Lactobacillus plantarum HEAL 19, DSM 15313.
 
5. Lactobacillus paracasei 8700:2, DSM 13434, zur Verwendung nach einem der Ansprüche 1 bis 4, wobei der Säuger ein Mensch ist.
 
6. Zusammensetzung, die Lactobacillus paracasei 8700:2, DSM 13434, umfasst, nach einem der Ansprüche 1 bis 5, zur Verwendung bei der Erhöhung der Absorption von Ca2+-Ionen bei der Behandlung oder Vorbeugung von Osteoporose und/oder bei der Erhöhung der Absorption von Ca2+-Ionen bei der Behandlung oder Vorbeugung von Knochenschwund bei einem Säuger, wobei die Zusammensetzung zusätzlich mindestens einen Träger umfasst.
 
7. Zusammensetzung, die Lactobacillus paracasei 8700:2, DSM 13434, umfasst, zur Verwendung nach Anspruch 6, wobei die Zusammensetzung in Form eines Lebensmittelprodukts, einer Nahrungsergänzung, eines medizinischen Lebensmittels, eines funktionellen Lebensmittels oder eines Ernährungsprodukts bereitgestellt wird.
 
8. Lactobacillus paracasei 8700:2, DSM 13434, zur Verwendung nach einem der Ansprüche 1 bis 5, oder eine Zusammensetzung, die Lactobacillus paracasei 8700:2, DSM 13434, umfasst, zur Verwendung nach Anspruch 6 oder 7, wobei die Laktobazillen in einer Menge von etwa 1 x 106 bis etwa 1 x 1014 KBE vorhanden sind.
 
9. Lactobacillus paracasei 8700:2, DSM 13434, zur Verwendung nach Anspruch 8 oder eine Zusammensetzung, die Lactobacillus paracasei 8700:2, DSM 13434, umfasst, zur Verwendung nach Anspruch 8, wobei die Laktobazillen in einer Menge von etwa 1 x 108 bis etwa 1 x 1012 KBE vorhanden sind.
 
10. Lactobacillus paracasei 8700:2, DSM 13434, zur Verwendung nach Anspruch 9 oder eine Zusammensetzung, die Lactobacillus paracasei 8700:2, DSM 13434, umfasst, zur Verwendung nach Anspruch 9, wobei die Laktobazillen in einer Menge von etwa 1 x 109 bis etwa 1 x 1011 KBE vorhanden sind.
 
11. Lactobacillus paracasei 8700:2, DSM 13434, zur Verwendung nach einem der Ansprüche 1 bis 5 oder 8 bis 10, oder eine Zusammensetzung, die Lactobacillus paracasei 8700:2, DSM 13434, umfasst, zur Verwendung nach einem der Ansprüche 6 bis 10, wobei die Osteoporose eine postmenopausale Osteoporose ist.
 


Revendications

1. Lactobacillus paracasei 8700:2, DSM 13434, destiné à être utilisé pour augmenter l'absorption d'ions Ca2+ dans le traitement ou la prévention de l'ostéoporose, et/ou pour augmenter l'absorption d'ions Ca2+ dans le traitement ou la prévention de déperdition osseuse, chez un mammifère.
 
2. Lactobacillus paracasei 8700:2, DSM 13434, destiné à être utilisé selon la revendication 1, en combinaison avec au moins une souche probiotique de Lactobacillus plantarum.
 
3. Lactobacillus paracasei 8700:2, DSM 13434, destiné à être utilisé selon la revendication 2, dans lequel ladite au moins une souche probiotique de Lactobacillus plantarum est choisie parmi le Lactobacillus plantarum 299, DSM 6595, le Lactobacillus plantarum 299v, DSM 9843, le Lactobacillus plantarum HEAL 9, DSM 15312, le Lactobacillus plantarum HEAL 19, DSM 15313 et le Lactobacillus plantarum HEAL 99, DSM 15316.
 
4. Lactobacillus paracasei 8700:2, DSM 13434, destiné à être utilisé selon la revendication 1, en combinaison avec le Lactobacillus plantarum HEAL 9, DSM 15312 et le Lactobacillus plantarum HEAL 19, DSM 15313.
 
5. Lactobacillus paracasei 8700:2, DSM 13434, destiné à être utilisé selon l'une quelconque des revendications 1 à 4, dans lequel le mammifère est un humain.
 
6. Composition comprenant le Lactobacillus paracasei 8700:2, DSM 13434, selon l'une quelconque des revendications 1 à 5, destinée à être utilisée pour augmenter l'absorption d'ions Ca2+ dans le traitement ou la prévention de l'ostéoporose, et/ou pour augmenter l'absorption d'ions Ca2+ dans le traitement ou la prévention de la déperdition osseuse, chez un mammifère, la composition comprenant en outre au moins un porteur.
 
7. Composition comprenant le Lactobacillus paracasei 8700:2, DSM 13434, destinée à être utilisée selon la revendication 6, ladite composition se présentant sous la forme d'un produit alimentaire, d'un complément alimentaire, d'un aliment médical, d'un aliment fonctionnel ou d'un produit nutritionnel.
 
8. Lactobacillus paracasei 8700:2, DSM 13434, destiné à être utilisé selon l'une quelconque des revendications 1 à 5, ou composition comprenant Lactobacillus paracasei 8700:2, DSM 13434, destinée à être utilisée selon la revendication 6 ou 7, dans laquelle les Lactobacilli sont présents en une quantité d'environ 1x106 à environ 1x1014 CFU.
 
9. Lactobacillus paracasei 8700:2, DSM 13434, destiné à être utilisé selon la revendication 8 ou composition comprenant le Lactobacillus paracasei 8700:2, DSM 13434, destinée à être utilisée selon la revendication 8, les Lactobacilli étant présents en une quantité d'environ 1x108 à environ 1x1012 CFU.
 
10. Lactobacillus paracasei 8700:2, DSM 13434, destiné à être utilisé selon la revendication 9 ou composition comprenant le Lactobacillus paracasei 8700:2, DSM 13434, destinée à être utilisée selon la revendication 9, les Lactobacilli étant présents en une quantité d'environ 1x109 à environ 1x1011 CFU.
 
11. Lactobacillus paracasei 8700:2, DSM 13434, destiné à être utilisé selon l'une quelconque des revendications 1 à 5 ou 8 à 10, ou composition comprenant le Lactobacillus paracasei 8700:2, DSM 13434, destinée à être utilisée selon l'une quelconque des revendications 6 à 10, l'ostéoporose étant l'ostéoporose post-ménopausique.
 




Drawing























Cited references

REFERENCES CITED IN THE DESCRIPTION



This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description




Non-patent literature cited in the description